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Abstract
Background: Robust data on the contemporary management of atrial fibrillation (AF) patients in China are limited.
Importantly current practice in AF management has changing dramatically in recent years. Data from a large registry
study will enable us to evaluate the uptake and outcomes with different therapies in a large Chinese AF population.
Methods/Design: The Chinese Atrial Fibrillation Registry study (CAFR) aims to enroll 20,000 consecutive atrial
fibrillation (AF) patients from 32 tertiary and non-tertiary hospitals in Beijing, China, and follow up these patients every
6 months until 2020. Key data collected includes basic sociodemographic information, symptoms and signs, medical
history, results of physical examination and laboratory test, details of treatments and personal insurance status. For
patients who consent, 5 ml of blood sample will be stored at −80 °C for future analyses of biomarkers. At each
6 month follow up visit, data relating to clinical outcomes will be collected. Data from a randomly selected 10 % of
patients will be internally validated with their raw source data. Ischemic stroke events will be adjudicated by an
independent endpoint committee.
Discussion: CAFR will be one of the largest registries of Asian AF patients (and the largest in Chinese AF patients), as
well as providing the longest follow up. This study would provide a valuable opportunity for ‘real world’ clinical
epidemiology with insights into the uptake (and outcomes) of contemporary AF management.
Trial registration: Chinese Clinical Trial Registry ChiCTR-OCH-13003729. Registered 22 October 2013.
Keywords: Atrial fibrillation, Registry study, China
Background
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia and carries an increased risk of
stroke, hospitalization, and mortality [1, 2]. It is esti-
mated that at least 10 million patients in China suffer
from AF [3]. With the ageing population and associated
prevalence of other cardiovascular diseases, the burden
of AF is projected to increase even further in China.
Although AF has been identified as a major risk factor
for stroke, recommendations on anticoagulation therapy
in Asian population are inconsistent in several aspects,
including criteria for anticoagulation and the intensity of
warfarin use. There is a perception that Asians are more
prone to bleeding (especially intracranial bleeding) on
warfarin [4, 5] and some guidelines even recommend
that the Asian population should target a lower inter-
national normalized ratio (INR) range (eg. 1.6–2.6) when
warfarin is used [5, 6]. Despite limited evidence support-
ing this practice, Chinese doctors tend to be conser-
vative when prescribing oral anticoagulation (OAC)
therapy for AF patients, reflected by an extremely low
usage of OAC. When warfarin is prescribed, a lower
INR is usually targeted. Indeed, limited data on quality
of anticoagulation control (as reflected by time in thera-
peutic range, TTR) are available from Asian cohorts,
despite TTR being closely related to the efficacy and
safety of warfarin [7].
Thus, real world data may provide additional evidence
to guide our practice when evidence from randomized
trial is less likely to be obtained. In addition, the
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treatment of AF is changing in many ways in China. For
example, catheter ablation is provided in majority of
tertiary hospitals despite the shortage of evidence sup-
porting its effectiveness on patient centered outcomes.
Non-Vitamin K antagonist oral anticoagulants (NOACs)
are increasingly prescribed whilst data of effectiveness
and safety of these agents is more limited among
Chinese population. Left atrial appendage occlusion was
introduced in China in the last 2 years and real world
data would be valuable in evaluating the effectiveness of
this new technique.
Third, we recognize that genetic susceptibility contrib-
utes to the development of some diseases and the
patients’ response to therapy [8]. Indeed, some patients
with paroxysmal AF will not progress to persistent AF
for many years while others progress more quickly.
Stroke also happens in some AF patients without any
known risk factors. Incorporating phenotype and geno-
type studies will provide the opportunity for better
understanding of AF as a disease entity and for personal-
ized treatment.
The Chinese Atrial Fibrillation Registry study (CAFR)
is a prospective registry study launched in August 2011
and is still ongoing. Herein we reported the rationale,
design of this study and current status of the database.
Research objectives
CAFR aims to provide evidence for clinical practice
based on real world data. The main objectives are as
follows: (i) to compare and validate current risk scores
for stroke and bleeding risk assessment in Chinese AF
patients; consequent upon this, to improve current risk
prediction models using phenotype and genotype data;
(ii) to study factors associated with anticoagulation
under-use, variation in stroke prevention practice and
progress over the study period in typical tertiary and
non-tertiary hospitals; and (iii) to report on safety and
long term effectiveness of AF ablation therapy, and
compare the effectiveness of ablation and medical ther-
apy in reducing death and thromboembolic events, using
propensity score matched cohorts.
The following additional exploratory analyses will also
be considered: (i) description of effectiveness and safety
of NOACs and left atrial appendage closure among the
Chinese AF population; and (ii) assessment of bio-
markers associated with AF progression from paroxys-
mal to persistent AF, and development of complications.
Methods/Design
Study setting
Thirty two tertiary and non-tertiary hospitals at where
the majority of AF patients in Beijing are managed,
have agreed to participate in this study. The character-
istics of participating hospitals are listed in Table 1.
Patient inclusion and exclusion criteria
Patients aged 18 years or older with a documented AF as
confirmed by 12 leads ECG, pacemaker/ICD electrocardio-
gram, or Holter ECG (duration of AF episode least 30 s)
are eligible for this study. Patients with transient AF caused
by reversible cause (e.g., cardiac surgery, pulmonary em-
bolism, untreated hyperthyroidism) or combined with
other serious diseases with a life expectancy < 1 year were
excluded. All patients with the diagnosis of AF who are
under the care of cardiologists or general physicians in the
participating hospitals, and provided informed consent will
be enrolled, from both outpatient and inpatient settings.
Each hospital maintained an admission record to provide
evidence of whether there was selection bias, by comparing
the mean age, sex and comorbidities of enrolled and non-
enrolled patients. Enrollment will cease when the target of
20000 patients is achieved.
Clinical data collection
Key data elements and definition of each variable were
in line with the ACC/AHA recommendation on AF
clinical data standards [9] and international peer studies
[10] to facilitate cross-comparison of results between
different registries. The following data were collected for
each patient enrolled: basic socio-demographic informa-
tion, symptoms and signs relating to AF, medical history,
results of physical examination and laboratory test and
patient self-reported quality of life (using a validated
Chinese version of AFEQT questionnaire). For patients
undergoing ablation therapy, detailed procedure related
information is also collected, including the pathway of
ablation, achievement of conduction block, time con-
sumed and peri-procedure complications.
Each enrolled patient will be followed up every 6 months
by trained staff, at outpatient clinic or through telephone
interview. Information relating to medical therapies, health-
care utilization, and clinical outcomes will be collected dur-
ing follow up. Definition of the major outcome events are
provided in Table 2. Every patient will be followed up until
2020. The questionnaires used for data collection in study
are provided in appendix. All the data were entered into a
specific electronic data capture system.
Blood sample for future analysis
Five milliliter venous blood sample will be collected from
patients with consent. The sample will be centrifuged.
Table 1 Characteristics of participating hospitals
Tertiary hospitals Non-tertiary hospitals
No of hospitals 20 12
No. of beds for cardiovascular
disease, Median (IQR)
78 (59–120) 46.5 (12–80)
AF ablation facilities 18/20 (90 %) 0/12 (0 %)
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Plasma and blood cells will be separately stored at −80 °C
refrigerators. Standard operation procedures for blood
collection, processing and archiving are in line with the
International Society for Biological and Environmental Re-
positories’ Best Practices for Repositories [11]. FreezerPro®
is used for web-based management of frozen samples and
information of sample will be linked to corresponding
clinical data.
Data management and quality control
All clinical data will be captured via a web-based elec-
tronic data capture (EDC) system. Investigators will
enter and edit the data via a secure network, with secure
access features. Variables related to the answer of main
aims are mandatory to be entered. The database also
had function of range and logic check. Source material
will be kept in hospital for further monitoring and audit-
ing. The quality control team will review all the data
collected case by case and send queries when applicable.
A random selection of 10 % cases will have their raw
data validated, for baseline data collection and during
each follow up. All reported ischemic stroke and periph-
eral embolism events will be adjudicated by an inde-
pendent endpoint committee.
Ethical considerations
Ethics approval was obtained from the Human Research
Ethics Committees at Beijing Anzhen Hospital. Ethic
review boards in each participating hospital agreed their
participation. The data collected will be held centrally in
a secure database, only de-identified information can be
used for analysis. Informed consent from individual
patients was sought for their agreement to participate in
long-term follow-up and usage of their blood sample for
further analysis. The study was performed according to
the ethical principles for medical research involving
human subjects specified in the Declaration of Helsinki.
Statistical analysis
The CHADS2 schema and CHA2DS2-VASc schema will
be compared and validated in these Chinese AF patients,
after excluding patients receiving anticoagulation ther-
apy or ablation therapy during follow up. Logistic regres-
sion will be used to evaluate the predictive value of the
various risk schemata in discriminating between patients
who develop the outcome of interest and those who do
not. The c-statistic will be estimated to determine the
predictive ability for stroke of each schema. The 95 %
confidence interval will be estimated for the c-statistic
using a non-parametric bias-corrected bootstrapping
method. To assess the effect of individual risk factors on
the occurrence of events, multivariable logistic regres-
sion will be used with the baseline covariates as inde-
pendent variables. According to the result of the
multivariable logistic regression analysis, the score for
each risk factor will be adjusted for the best fitted classi-
fication schema. If necessary, new risk factors may also
be added to generate a new stroke risk classification
schema for Chinese AF population. The new schema will
be validated on the validation population and the C-
statistics will be calculated using the new risk schema. In
Table 2 Outcomes collected and associated definitions
Outcomes Definitions
Primary outcome
Composite outcome of any of the following events:
all-cause mortality, non-fatal ischemic stroke and
peripheral embolism.
All-cause mortality: All deaths regardless of etiology
Non-fatal Ischemic stroke: Documented stroke or cerebrovascular accident consisting
of acute loss of neurological function caused by an ischemic event with residual
symptoms at least 24 hours after onset.
Peripheral embolism: Abrupt vascular insufficiency associated with clinical and
radiological evidence of arterial occlusion in a vascular bed other than the
cerebrovascular system in the absence of other likely mechanisms (e.g.,
atherosclerosis).
Secondary outcomes
Component of the primary composite outcome including:
1) all-cause mortality; 2) non-fatal stroke or peripheral
embolism.
As above
Intracranial hemorrhages Bleeding into or around the brain, including 1) Hemorrhagic conversion of a
primary ischemic stroke; 2) Subarachnoid hemorrhage; 3) Intra-cerebral
hemorrhage; 4) Other (including subdural and epidural hematomas);
Major bleeding Bleeding leads to 1) Transfusion of at least 2 units of whole blood or erythrocytes;
2) Requiring hospitalization or surgery; 3) Resulting in permanent disability;
4) Involving a critical anatomic site (retroperitoneal, pericardial, intra-spinal,
intracranial, non-traumatic intra-articular, or intra-ocular bleeding associated with
abrupt deterioration of visual acuity).
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addition, the net reclassification index will also be used
to evaluate predictive value of the prognostic score.
To compare the ablation and non-ablation therapies,
propensity score matching for receiving catheter ablation
will be calculated for each patient based on a multivari-
able logistic regression model. Baseline characteristics
variables which are assumed to be associated with the
probability of having catheter ablation will be included
in the model as independent variables. Based on the pro-
pensity scores, ablation and non-ablation patients will be
matched on a 1:1 basis with a combination of the near-
est neighbor algorithm and caliper algorithm [12]. For
each ablation patient, a non-ablation patient with the
smallest propensity score difference, and smaller than
0.02, will be matched without replacement. Patients not
matched will be excluded from the analysis.
Unadjusted event rates for the composite primary out-
come of time to first all-cause mortality, stroke and per-
ipheral embolism for the propensity-matched ablation
and non-ablation groups will be estimated using the
Kaplan-Meier method and compared between groups
with the log-rank test. As sensitivity analyses, the inverse
probability of treatment weighting using propensity
score will also be used to compare the survival distribu-
tions between ablation and non-ablation group.
Sample size calculation
For the objective of developing the optimal risk predic-
tion model for Chinese AF population, a minimum of
200 events (i.e. 10 times of the variable number) are re-
quired to accommodate 20 variables in the prediction
model. The analysis is planned to be done in 2015 to ac-
cumulate enough events for analysis. For that purpose,
about 5000 patients without anticoagulation therapy are
required for an evenly splitted training cohort and valid-
ation cohort. For the objective of evaluating the effect-
iveness of ablation therapy, the following assumption is
made: the accumulate ischemic stroke and intracranial
hemorrhage is 10 % in optimally anticoagulated patients
and 7 % in ablation patients in five years, 1800 matched
patients in each arm are required to provide 90 % power
to detect the difference (α = 0.05). As those two groups
of patients are quite different, we amplified the sample
size by 3 times to guarantee enough matched patients.
In total, 16000 patients are required for the main ana-
lyses and considering a possible 20 % withdraw and loss
of follow up, we up round the sample size to 20000.
Results
Current status and data quality
17467 patients had been enrolled as at June 30, 2015.
The majority (84.0 %) came from tertiary hospitals
where most AF patients are managed. The missing rates
for the key variables are listed in Table 3. There are no
missing data among the mandatory variables which is
controlled by the EDC system. Out of range variables
were very rare (<0.1 %) for those with range check.
Patient follow up rates at 6, 12, 18 and 24 months are
93, 91, 87 and 85 % respectively.
Discussion
This large, contemporary, longititudinal study of Chinese
AF patients will provide a unique opportunity to answer
Table 3 Variables collected in the CAFR study and missing rate






Age or Date of Birth 17467 0 %
Sex 17467 0 %
Date of initial register 17467 0 %
Type of AF 17340 0.73 %
Systolic blood pressure 17291 1.01 %
Height 15845 9.29 %
Body weight 15964 8.60 %
History of alcohol-drinking 17250 1.24 %
History of hypertension 17331 0.78 %
History of diabetes mellitus 17331 0.78 %
History of hyperlipidemia 17288 1.02 %
History of heart failure 17331 0.78 %
History of myocardial infarction 17328 0.80 %
History of coronary artery disease 17330 0.78 %
Signs of heart failure 17329 0.79 %
Hemoglobin level 13552 22.4 %
Creatinine level 14264 18.3 %
Fasting blood glucose 13718 21.4 %
Total cholesterol 13587 22.2 %
Is thyroid function within normal range 12367 29.2 %
Left ventricular ejection fraction 13568 22.3 %
History of direct current cardioversion 17268 1.14 %
History of radiofrequency ablation 17332 0.77 %
History of ischemic stroke/transient
ischemia attach/ peripheral arterial
thromboembolism
17338 0.74 %
History of intracranial hemorrhage/
other major bleeding
17335 0.76 %
Use antiarrhythmic agents 17334 0.76 %
Use ventricular rate control agents 17332 0.77 %
use antithrombotic agents 17333 0.77 %
Warfarin 17281 1.06 %
Use Angiotensin converting enzyme
inhibitors/angiotensin receptor blockers
17281 1.06 %
Use Statins 17283 1.05 %
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many clinical questions and to expand our knowledge of
AF development and treatment.
The CAFR study is important in several respects. First,
systematic observational data can be generated from this
registry study, which is especially valuable given that
evidence for Chinese AF patients is limited. Results from
randomised clinical trials remain the most robust
evidence for clinical decision making, these can be
expensive and time consuming to be feasible in many
scenerios. Second, treatment of AF is changing dramat-
ically. For example, ablation therapy is increasingly
widely provided while there is short of evidence to
support the practice, especially in the Chinese AF popu-
lation. NOACs have proved their efficacy in stroke pre-
vention [13–17] but whether the efficacy observed in
randomized trials translates into effectiveness and safety
in Chinese AF patients need to be evaluated in real
world studies. Third, the CAFR study provides a good
opportunity to compare treatment and response vari-
ation among AF populations in China, for comparison
with different countries. Currently, several other large
AF registries are ongoing. The main characteristics of
large size registry studies are listed in Table 4.
The CAFR study is unique compared with other AF
registry studies in the following respects: (i) CAFR is the
largest real world study among Asian AF patients and
will generate invaluable data for this patient group; (ii)
CAFR is a longitudinal study which enable evaluation of
long term effects of specific therapies; and (iii) A high
proportion of patients had their blood sample taken,
which enables investigation of genetic and environment
interactions in the developement and treatment of AF.
Limitations
Participating hospitals of this study are all hospitals in
urban and semi-urban area of Beijing, the capital of
China. However, about half of the registied patients
come from all around the country, which increases the
representativeness of the study population. In addition,
the majority of patients are registred from tertiary hospi-
tals, but this reflects current practice of Chinese medical
care as the mechanisms of referral are not fully estab-
lished and patients usually go direct to terriary hospitals
without referral from primary health care providers.
Despite these limitations, we feel that we are unlikely
to overtly bias conclusions for the prespecified main
analysis of this study.
Conclusion
CAFR will be one of the largest registries of Asian AF
patients (and the largest in Chinese AF patients), as well
as providing the longest follow up. This study would
provide a valuable opportunity for ‘real world’ clinical
epidemiology with insights into the uptake (and out-
comes) of contemporary AF management.
Additional file
Additional file 1: Ethics committees of CAFR. (DOCX 20 kb)
Table 4 Atrial fibrillation registry studies worldwide
Studies Participating centers Timeline Follow-up Sample size Main purpose
RHYTHM-AF [18] 10 countries, 175 centers,
mostly European countries
May 2010 ~June 2011 60 days 3940 To describe treatment patterns
and short term outcomes related
to cardioversion.
GARFIELD [19] 50 countries in Europe,
Asia-Pacific, Central/South
America, and Canada
Started in December 2009,
with a planned recruitment
period of 4 years
2-year 55,000 To evaluate the management
and outcomes of patients with
newly diagnosed non-valvular AF
at risk for stroke.
GLORIA-AF [20] Nearly 50 countries in Asia,
Europe, North America,
Latin America and Africa/
Middle East
Phase I: May 2011-
January 2013.
Phase II: 2 years 56,000 To investigate patient
characteristics influencing choice
of antithrombotic treatment and
to collect data on outcomes of
antithrombotic therapy
Phase II: November 2011 Phase III: 3 years
Phase III: early 2014
J-RHYTHM [21] 158 institutions in Japan January to July 2009 2-year 7937 To determine the appropriate
INR for Japanese AF patients




72 centers in 10 European
countries
October 2010 1 year 1410 to describe the clinical
epidemiology and treatment of
patients undergoing AF ablation
ORBIT-AF [24] 200 US outpatient practices June 2010 to August 2011. ≥2 years 10097 To characterize treatment and
outcomes of patients with AF
Abbreviations: RHYTHM-AF International Registry on Cardioversion of Atrial Fibrillation, GARFIELD Global Anticoagulant Registry in the FIELD, GLORIA-AF Global
Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation, J-RHYTHM Japanese Rhythm Registry, PINNACLE-AF The nationwide US
Practice INNovation And Clinical Excellence Registry, ORBIT-AF The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
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Abbreviations
AF, atrial fibrillation; CAFR, Chinese atrial fibrillation registry; EDC, electronic
data capture; INR, international normalized ratio; NOAC, non-vitamin K




Jiyun Wang (Tongren Hospital, Capital Medical University), Xinchun Yang
(Chaoyang Hospital, Capital Medical University), Peng Huang (Civil Aviation
General Hospital), Jun Li (Guanganmen Hospital, Beijing), Hongwei Li (Youyi
Hospital), Ming Yang (Fuxing Hospital, Beijing), Hong Jiang (Sino-Japan
Friendship Hospital, Beijing), Xiaozhong Zhang (307 Hospital, Beijing),
Jie Jiang (Peking University First Hospital), Ping Zhang (Peking University
People’s Hospital), Qijun Shan (People’s Liberation Army General Hospital),
Quan Fang (Union Hospital, Beijing), Shuwang Liu (Peking University Third
Hospital), Xian Wang (Dongzhimen Hospital, Beijing), Yang Wu (Dongfang
Hospital, Beijing), xxx (Navy General Hospital), Qi Hua (Xuanwu Hospital),
Xingshan Zhao (Jishuitan Hospital), Lihua Shang (Huaxin Hospital), Haibin
Zhang (Luhe Hospital), Aijuan Liu (Miyun People’s Hospital), Jinping Wang
(Huayi Hospital), Ruijie Li (Chaoyang Second Hospital), Zhengyan Zhu (Shunyi
People’s Hospital), Xuemei Peng (Fangshan First Hospital), Lin Pi (Chuiyangliu
Hospital), Lantang Han (Daxing People’s Hospital), Weiju Li (Peking University
Hospital), Ling Sun (Jiugong Community Health Center), Chunhong Li
(Ganjiakou Community Health Center), Xudong Chen (Wangsiying
Community Health Center), Buxing Chen (Tiantan Hospital, Beijing).
Funding
CAFR study was funded by an unrestricted grant from Beijing Municipal
Science and Technology Commission provided to the Beijing Anzhen
Hospital, Beijing, China. Bristol-Myers Squibb, Pfizer, Boehringer-ingelheim,
Biosense Webster all sponsored this study. The sponsors of the study had no
role in study design, data collection, data analysis, data interpretation, or
writing of the report.
Availability of data and materials
Not applicable as this is a study protocol.
Authors’ contributions
XD participated in the design of the study, in the trial conduct and drafted
the manuscript. CM participated in its design and coordination and helped
to draft the manuscript. JW participated in the trial design and conduct. SL
participated in trial conduct. MN participated in trial conduct. RT participated
in trial conduct. XG participated in trial conduct and helped to draft the
manuscript. DL participated in trial conduct. RY participated in trial conduct.
CS participated in trial conduct. CJ participated in trial conduct. TZ participated
in the statistical analysis. JP participated in the statistical analysis. XL participated
in trial design and coordination. JD participated in trial design and coordination.
GL helped to draft the manuscript. All authors read and approved the final
manuscript.
Competing interests
All authors have completed the Unified Competing Interest form at
www.icmje.org/coi_disclosure.pdf (available on request from the corresponding
author) and declare that (1) CM has support from Bristol-Myers Squibb, Pfizer,
Boehringer-ingelheim, Biosense Webster for the submitted work; (2) No author
has relationships with companies that might have an interest in the submitted
work in the previous 3 years; (3) Their spouses, partners, or children have no
financial relationships that may be relevant to the submitted work; and (4) No




Ethics approval and consent to participate
The individual ethics committees are named in the Additional file 1.
Author details
1Beijing Anzhen Hospital, Capital Medical University, No 2 Anzhen Road,
Chaoyang District, Beijing 100029, China. 2Peking University Clinical Research
Institute, Beijing, China. 3University of Birmingham Institute of Cardiovascular
Sciences, City Hospital, Birmingham, UK.
Received: 3 February 2016 Accepted: 30 May 2016
References
1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ,
et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of
Disease 2010 Study. Circulation. 2014;129:837–47.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D.
Impact of atrial fibrillation on the risk of death: the Framingham Heart
Study. Circulation. 1998;98:946–52.
3. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation
in the Chinese population of mainland China. J Epidemiol. 2008;18:209–16.
4. Shen A, Yao J, Brar S, Jorgensen M, Chen W. Racial/Ethnic Differences in the
Risk of Intracranial Hemorrhage Among Patients With Atrial Fibrillation.
J Am Coll Cardiol. 2007;50:309–15.
5. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian
perspective. Thromb Haemost. 2014;111:789–97.
6. Ma C. Current antithrombotic treatment in East Asia: some perspectives on
anticoagulation and antiplatelet therapy. Thromb Haemost. 2012;107:1014–8.
7. Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ,
et al. Safety and efficacy of well managed warfarin. A report from the
Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–7.
8. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, et al.
Atrial fibrillation: current knowledge and future directions in epidemiology
and genomics. Circulation. 2011;124:1982–93.
9. McNamara RL, Brass LM, Drozda Jr JP, Go AS, Halperin JL, Kerr CR, et al.
ACC/AHA key data elements and definitions for measuring the clinical
management and outcomes of patients with atrial fibrillation: a report of
the American College of Cardiology/American Heart Association Task Force
on Clinical Data Standards (Writing Committee to Develop Data Standards
on Atrial Fibrillation). Circulation. 2004;109:3223–43.
10. Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation
in warfarin use among outpatients with atrial fibrillation (from the NCDR
PINNACLE program). Am J Cardiol. 2011;108:1136–40.
11. Collection, storage, retrieval and distribution of biological materials for
research. https://isber.site-ym.com/?page=BPR. Accessed 5 Jun 2016.
12. Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for
confounding control in nonexperimental research. Circ Cardiovasc Qual
Outcomes. 2013;6:604–11.
13. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med.
2009;361:1139–51.
14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
15. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med.
2011;365:981–92.
16. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al.
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med.
2013;369:2093–104.
17. Alli O, Doshi S, Kar S, Reddy V, Sievert H, Mullin C, et al. Quality of life
assessment in the randomized PROTECT AF (Percutaneous Closure of the
Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in
Patients With Atrial Fibrillation) trial of patients at risk for stroke with
nonvalvular atrial fibrillation. J Am Coll Cardiol. 2013;61:1790–8.
18. Crijns HJ, Bash LD, Chazelle F, Le Heuzey JY, Lewalter T, Lip GY, et al.
RHYTHM-AF: design of an international registry on cardioversion of atrial
fibrillation and characteristics of participating centers. BMC Cardiovasc
Disord. 2012;12:85.
19. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al.
International longitudinal registry of patients with atrial fibrillation at risk of
stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J.
2012;163:13–9.
20. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design
and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment
in Patients with Atrial Fibrillation: A global registry program on long-term oral
antithrombotic treatment in patients with atrial fibrillation. Am Heart J.
2014;167:329–34.
Du et al. BMC Cardiovascular Disorders  (2016) 16:130 Page 6 of 7
21. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, for the JRHYTHM
Registry investigators. Investigation of optimal anticoagulation strategy for
stroke prevention in Japanese patients with atrial fibrillation: The J-RHYTHM
Registry study design. J Cardiol. 2011;57:95–9.
22. American College of Cardiology launches PINNACLE-AF: Outpatient registry
to focus on atrial fibrillation treatment http://www.ncdr.com/WebNCDR/
docs/pinnacle-public-documents/pinnacle-af-press-release-fin.pdf?sfvrsn=2.
Accessed 5 Jun 2016.
23. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, et al. The
atrial fibrillation ablation pilot study: an European Survey on Methodology
and * results of catheter ablation for atrial fibrillation: conducted by the
European Heart Rhythm Association. Eur Heart J. 2014;35:1466–78.
24. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, et al.
Outcomes registry for better informed treatment of atrial fibrillation:
rationale and design of ORBIT-AF. Am Heart J. 2011;162:606.e1–12.e1.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Du et al. BMC Cardiovascular Disorders  (2016) 16:130 Page 7 of 7
